Synthesis and characterization of an 111In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR)

Bioconjugate Chemistry

Volumn 20, Issue 5, 2009, Pages 888-894

  Liu, Dijie ^a,c   Overbey, Douglas ^a,c   Watkinson, Lisa ^a,c   Giblin, Michael F ^a,b,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d A004 HSTMVH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; INDIUM 111; SMALL INTERFERING RNA; UROKINASE RECEPTOR; INDIUM; PEPTIDE FRAGMENT; UROKINASE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONJUGATION; CONTROLLED STUDY; IC 50; IMMUNOBLOTTING; IN VIVO STUDY; ISOTOPE LABELING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCID MOUSE; SYNTHESIS; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MOLECULAR IMAGING; PATHOLOGY; TUMOR CELL LINE;

MUS;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIUM RADIOISOTOPES; MICE; MOLECULAR IMAGING; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 66149160374     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800433y     Document Type: Article

References (34)

1. Blasi, F., and Carmeliet, P. (2002) uPAR: a versatile signaling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943.
2. Ploug, M. (2003) Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr. Pharm. Des. 9, 1499-1528. (Pubitemid 36758313)
3. Romer, J., Nielsen, B. S., and Ploug, M. (2004) The urokinase receptor as a potential target in cancer therapy. Curr. Pharm. Des. 10, 2359-2376. (Pubitemid 38855042)
4. Danø, K., Behrendt, N., Høyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., and Rømer, J. (2005) Plasminogen activation and cancer. Thromb. Haemost. 93, 676-681. (Pubitemid 40485402)
5. Xue, A., Scarlett, C. J., Jackson, C. J., Allen, B. J., and Smith, R. C. (2008) Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 36, 160-167.
6. Beyer, B. C., Heiss, M. M., Simon, E. H., Gruetzner, K. U., Babic, R., Jauch, K. W., Schildberg, F. W., and Allgayer, H. (2006) Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 106, 1026-1035. (Pubitemid 43297340)
7. Holst-Hansen, C., Johannessen, B., Hoyer-Hansen, G., Romer, J., Ellis, V., and Brunner, N. (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin. Exp. Metastasis 14, 297-307. (Pubitemid 26246575)
8. Boyd, D. D., Kim, S., Wang, H., Jones, T. R., and Gallick, G. E. (2003) A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am. J. Pathol. 162, 619-626.
9. Boyd, D. D., Wang, H., Avila, H., Parikh, N. U., Kessler, H., Magdolen, V., and Gallick, G. E. (2004) Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin. Cancer Res. 10, 1545-1555. (Pubitemid 38365251)
10. Yang, L., Avila, H., Wang, H., Trevino, J., Gallick, G. E., Kitadai, Y., Sasaki, T., and Boyd, D. D. (2006) Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density -- implications in tumor progression. Cancer Res. 66, 7957-7967. (Pubitemid 44299159)
11. Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brünner, N., Jänicke, F., Meijervan Gelder, M. E., Henzen-Logmans, S. C., van Putten, W. L., and Klijn, J. G. (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60, 636-643. (Pubitemid 30094561)
12. Reuning, U., Sperl, S., Kopitz, C., Kessler, H., Krüger, A., Schmitt, M., and Magdolen, V. (2003) Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr. Pharm. Des. 9, 1529-1543. (Pubitemid 36758314)
13. Stoppelli, M. P., Corti, A., Soffientini, A., Cassani, G., Blasi, F., and Assoian, R. K. (1985) Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. U.S.A. 82, 4939-4943. (Pubitemid 15249921)
14. Goodson, R. J., Doyle, M. V., Kaufman, S. E., and Rosenberg, S. (1994) High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. U.S.A. 91, 7129-7133. (Pubitemid 24226816)
15. Ploug, M., Ostergaard, S., Gardsvoll, H., Kovalski, K., Holst- Hansen, C., Holm, A., Ossowski, L., and Dano, K. (2001) Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40, 12157-12168. (Pubitemid 32946557)
16. Knör, S., Sato, S., Huber, T., Morgenstern, A., Bruchertseifer, F., Schmitt, M., Kessler, H., Senekowitsch-Schmidtke, R., Magdolen, V., and Seidl, C. (2008) Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 53-64. (Pubitemid 350234153)
17. Li, Z., Niu, G., He, L., Yang, L., Ploug, M., and Chen, X. (2008) Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin. Cancer Res. 14, 4758-4766.
18. 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J. Nucl. Med. 45, 1381-1389.
19. Hoffman, T. J., Gali, H., Smith, C. J., Sieckman, G. L., Hayes, D. L., Owen, N. K., and Volkert, W. A. (2003) Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J. Nucl. Med. 44, 823-831. (Pubitemid 39655218)
20. Giblin, M. F., Gali, H., Sieckman, G. L., Owen, N. K., Hoffman, T. J., Forte, L. R., and Volkert, W. A. (2004) In vitro and in vivo comparison of human Escherichia coli heat-stable peptide analogues incorporating the 111In-DOTA group and distinct linker moieties. Bioconjugate Chem. 15, 872-880.
21. Giblin, M. F., Wang, N., Hoffman, T. J., Jurisson, S. S., and Quinn, T. P. (1998) Design and characterization of alphamelanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc. Natl. Acad. Sci. U.S.A. 95, 12814-12818. (Pubitemid 28509480)
22. 111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J. Nucl. Med. 46, 1561-1569.
23. Wu, Y., Zhang, X., Xiong, Z., Cheng, Z., Fisher, D. R., Liu, S., Gambhir, S. S., and Chen, X. (2005) microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46, 1707-1718.
24. Arens, N., Gandhari, M., Bleyl, U., and Hildenbrand, R. (2005) In vitro suppression of urokinase plasminogen activator in breast cancer cells -- a comparison of two antisense strategies. Int. J. Oncol. 26, 113-119.
25. Hansen, A. P., Petros, A. M., Meadows, R. P., Nettesheim, D. G., Mazar, A. P., Olejniczak, E. T., Xu, R. X., Pederson, T. M., Henkin, J., and Fesik, S. W. (1994) Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 33, 4847-4864. (Pubitemid 24158434)
26. Guthaus, E., Schmiedeberg, N., Burgle, M., Magdolen, V., Kessler, H., and Schmitt, M. (2003) The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction. Recent Results Cancer Res. 162, 3-14.
27. Appella, E., Robinson, E. A., Ullrich, S. J., Stoppelli, M. P., Corti, A., Cassani, G., and Blasi, F. (1987) The receptor-binding sequence of urokinase. A biological function for the growthfactor module of proteases. J. Biol. Chem. 262, 4437-4440.
28. Huai, Q., Mazar, A. P., Kuo, A., Parry, G. C., Shaw, D. E., Callahan, J., Li, Y., Yuan, C., Bian, C., Chen, L., Furie, B., Furie, B. C., Cines, D. B., and Huang, M. (2006) Structure of human urokinase plasminogen activator in complex with its receptor. Science 311, 656-659. (Pubitemid 43191309)
29. Llinas, P., Le Du, M. H., Gårdsvoll, H., Danø, K., Ploug, M., Gilquin, B., Stura, E. A., and Ménez, A. (2005) Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 24, 1655-1663. (Pubitemid 40704976)
30. Setyono-Han, B., Stürzebecher, J., Schmalix, W. A., Muehlenweg, B., Sieuwerts, A. M., Timmermans, M., Magdolen, V., Schmitt, M., Klijn, J. G., and Foekens, J. A. (2005) Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb. Haemost. 93, 779-786. (Pubitemid 40485417)
31. Pulukuri, S. M., Gondi, C. S., Lakka, S. S., Jutla, A., Estes, N., Gujrati, M., and Rao, J. S. (2005) RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 280, 36529-36540. (Pubitemid 41633927)
32. Mohanam, S., Jasti, S. L., Kondraganti, S. R., Chandrasekar, N., Kin, Y., Fuller, G. N., Lakka, S. S., Kyritsis, A. P., Dinh, D. H., Olivero, W. C., Gujrati, M., Yung, W. K., and Rao, J. S. (2001) Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin. Cancer Res. 7, 2519-2526. (Pubitemid 32751658)
33. Law, B., Curino, A., Bugge, T. H., Weissleder, R., and Tung, C. H. (2004) Design, synthesis, and characterization of urokinase plasminogen-activator- sensitive near-infrared reporter. Chem. Biol. 11, 99-106. (Pubitemid 38203994)
34. Law, B., Weissleder, R., and Tung, C. H. (2007) Proteasesensitive fluorescent nanofibers. Bioconjugate Chem. 18, 1701-1704.